glycogen

yGsy2p-IN-1 is a potent inhibitor of yeast glycogen synthase 2 (yGsy2p) and human glycogen synthase 1 (hGYS1). Additionally, yGsy2p-IN-H23, a pyrazole inhibitor, is utilized in the treatment of glycogen storage diseases (GSDs).

PF-04802367 is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. It shows desirable central nervous system (CNS) properties and potency. It is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively.

GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.

Glycogen is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus.

Glycogen phosphorylase-IN-2 (compound 9C) is an inhibitor of glycogen phosphorylase, with a Ki value of 1.9 nM and an IC50 value of 4 nM.

Phospho-Glycogen Synthase Peptide-2, a substrate for glycogen synthase kinase-3 (GSK-3), serves as a peptide substrate effective in the affinity purification of protein-serine kinases.

Phospho-Glycogen Synthase Peptide-2 (substrate) serves as a peptide substrate for glycogen synthase kinase-3 (GSK-3) and is used for the affinity purification of protein-serine kinases [1].

[Glycogen Synthase (1-12) Ala9,10, Lys11,12] is a selective substrate for protein kinase C (PKC) phosphorylation. It serves to assess PKC activity [1].

Glycogen, Mussel is a glycolytic intermediate and high-energy phosphate that ACTS as a form of energy storage for humans, animals, fungi and bacteria.

CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.

5-Iodo-indirubin-3'-monoxime is a potent inhibitor of GSK-3β, CDK5/P25, and CDK1/cyclin B, competing with ATP for binding to the catalytic site of the kinase (IC50s: 9, 20, and 25 nM).

AVE5688, an inhibitor of glycogen phosphorylase (GP), has IC50 values of 430 nM and 915 nM, and Kd values of 170 nM and 530 nM for rmGPb and rmGPa, respectively. It is suitable for research on type 2 diabetes.

GNF4877 is a small molecule inhibitor, a potent dual-specificity kinase inhibitor targeting DYRK1A (IC50=6 nM) and GSK3β (IC50=16 nM). This compound promotes β-cell proliferation by blocking NFATc nuclear export (EC50=0.66 μM for mouse R7T1 cells) and is primarily used for research on β-cell regeneration related to diabetes.

R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.

Uric acid is an important antioxidant that scavenges oxygen radicals and reactive oxygen species (such as singlet oxygen and peroxynitrite), inhibits lipid peroxidation, helps maintain stable blood pressure, and is the final product of purine metabolism. It is commonly used to induce hypertension models.

Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.

Tideglusib (NP031112), a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3), is with anti-inflammatory and neuroprotective activities.

GSK3i XIII (GSK3 inhibitor XIII) is a GSK-3 ATP-binding site inhibitor.

VP3.15 dihydrobromide is a potent, orally bioavailable, and CNS-penetrant dual inhibitor of phosphodiesterase (PDE7) and glycogen synthase kinase (GSK)3, with IC50 values of 1.59 μM and 0.88 μM, respectively.

GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.

GSK-3β inhibitor 10 has skin-whitening, anti-oxidizing and PPAR activities.

A 1070722 is a potent and selective GSK-3 inhibitor, exhibiting high affinity for both GSK-3α (Ki = 0.6 nM) and GSK-3β (Ki = 0.6 nM). It can penetrate the blood-brain barrier (BBB) and accumulate in brain regions, indicating potential use as a PET radiotracer for quantifying GSK-3 in the brain.

BRD0705 is a potent, orally active GSK3α inhibitor with high selectivity (IC50: 66 nM; Kd: 4.8 μM), demonstrating an 8-fold higher selectivity for GSK3α compared to GSK3β (IC50: 515 nM).